Standout Papers

Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients wi... 2020 2026 2022 2024174
  1. Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma (2020)
    Xinan Sheng, Xieqiao Yan et al. Clinical Cancer Research

Immediate Impact

72 standout
Sub-graph 1 of 23

Citing Papers

Emerging Delivery Systems for Enabling Precision Nucleic Acid Therapeutics
2025 Standout
Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer
2025 Standout
2 intermediate papers

Works of Chang-Lu Hu being referenced

Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
2020 Standout

Author Peers

Author Last Decade Papers Cites
Chang-Lu Hu 167 162 69 104 17 357
Carrie B. Marshall 114 134 126 92 20 379
Armin Riecke 89 103 59 144 24 338
Sören Kneif 167 139 99 76 12 343
Katherine J. Blair 62 125 54 135 17 377
Weiqing Han 157 155 133 74 23 355
Mo‐Fa Gu 131 126 103 56 16 332
Nishan H. Fernando 124 256 140 83 13 385
Darren M. Kocs 107 216 135 145 16 397
Ayat Salman 98 119 37 66 23 392
Masaki Mori 163 115 117 149 15 388

All Works

Loading papers...

Rankless by CCL
2026